GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Institutional Ownership

argenx SE (argenx SE) Institutional Ownership : 48.31% (As of Apr. 28, 2024)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, argenx SE's institutional ownership is 48.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, argenx SE's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, argenx SE's Float Percentage Of Total Shares Outstanding is 0.00%.

argenx SE Institutional Ownership Historical Data

The historical data trend for argenx SE's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Institutional Ownership Chart

argenx SE Historical Data

The historical data trend for argenx SE can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 44.45 44.16 44.13 44.73 44.20 43.46 43.67 43.29 43.75 48.31

argenx SE Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

argenx SE (argenx SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Institutional Ownership
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.